admin – Page 3720 – Get News Story

Dravet Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Eisai, Stoke Therapeutics, EpyGenix Therapeutic, Marinus Pharma, Stoke Therapeutics, Jazz Pharma

The Key Dravet Syndrome Companies in the market include – Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, Marinus Pharmaceuticals, Stoke Therapeutics, Inc, Zogenix International Ltd, Inc., Jazz Pharmaceuticals, Ovid Therapeutics Inc., Longboard Pharmaceuticals, and others.

DelveInsight’s “Dravet Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Dravet Syndrome, historical and forecasted epidemiology as well as the Dravet Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dravet Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dravet Syndrome Market Forecast

Some of the key facts of the Dravet Syndrome Market Report:

The Dravet Syndrome market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In January 2025, Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on restoring protein expression through RNA-based medicine, has reached an agreement with global regulatory agencies on the design of its Phase 3 EMPEROR study. This trial aims to evaluate zorevunersen as a potential first disease-modifying treatment for Dravet syndrome.
In January 2025, The FDA awarded rare pediatric disease designation to relutrigine, a therapy developed by Praxis Precision Medicines for Dravet syndrome. This treatment is designed to help reduce seizures in children with epileptic disorders such as Dravet syndrome.
In December 2024, Stoke Therapeutics, Inc. announced that the FDA has granted Breakthrough Therapy Designation to zorevunersen for treating Dravet syndrome in patients with a confirmed SCN1A gene mutation that is not linked to gain-of-function.
In February 2024, The FDA has approved Encoded Therapeutics’ investigational new drug (IND) application for ETX101, allowing the company to initiate clinical trials for this gene therapy candidate aimed at treating Sodium channel protein type 1 subunit alpha (SCN1A)+ Dravet syndrome. Additionally, Australia’s TGA has granted approval under its Clinical Trial Approval (CTA) scheme for the trial to begin. ETX101 is an AAV9-mediated gene regulation therapy designed to enhance SCN1A gene expression in GABAergic inhibitory interneurons, targeting the root cause of Dravet syndrome. Encoded plans to launch a two-part Phase I/II clinical trial called ENDEAVOR in the US for patients aged six months to under three years in the first half of this year.
A new US epidemiological study, according to the Dravet Syndrome Foundation (2022), found that the prevalence of Dravet Syndrome, which affects 1:15,700 infants and 80% of whom had a SCN1A mutation, is twice as high as previously thought
The predicted total number of diagnosed cases of Dravet Syndrome in France in 2022 was 1,050, and by 2032, that number is expected to rise
It is projected that there will be approximately 1,000 treated instances of Dravet syndrome in the UK in 2022, and that number will rise by 2032
As to the company’s declaration, FINTEPLA’s net product sales amounted to around $75 million. In a similar vein, EPIDIOLEX’s net product sales in 2021 totaled $463.6 million.
A number of the newly developed Dravet syndrome treatments are in the late stages of clinical testing. These include lorcaserin and TAK-935 (soticlestat), both of which have demonstrated great promise in trials
Key Dravet Syndrome Companies: Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, Marinus Pharmaceuticals, Stoke Therapeutics, Inc, Zogenix International Ltd, Inc., Jazz Pharmaceuticals, Ovid Therapeutics Inc., Longboard Pharmaceuticals, and others
Key Dravet Syndrome Therapies: TAK-935 (soticlestat), BELVIQ (lorcaserin), STK-001, ganaxolone, EPX-100 (Clemizole HCl), STK-001, ZX008 (Fenfluramine Hydrochloride), GWP42003-P, Soticlestat, LP352, and others
The Dravet Syndrome epidemiology based on gender analyzed that more men than women have Dravet Syndrome
The Dravet Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dravet Syndrome pipeline products will significantly revolutionize the Dravet Syndrome market dynamics.

Dravet Syndrome Overview

Dravet syndrome, also known as severe myoclonic epilepsy of infancy (SMEI), is a rare and severe form of epilepsy that begins in infancy or early childhood. It is characterized by prolonged seizures, often triggered by fever, along with other types of seizures such as myoclonic, atonic, and absence seizures.

Get a Free sample for the Dravet Syndrome Market Report:

https://www.delveinsight.com/report-store/dravet-syndrome-market

Dravet Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dravet Syndrome Epidemiology Segmentation:

The Dravet Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Dravet Syndrome
Prevalent Cases of Dravet Syndrome by severity
Gender-specific Prevalence of Dravet Syndrome
Diagnosed Cases of Episodic and Chronic Dravet Syndrome

Download the report to understand which factors are driving Dravet Syndrome epidemiology trends @ Dravet Syndrome Epidemiology Forecast

Dravet Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dravet Syndrome market or expected to get launched during the study period. The analysis covers Dravet Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dravet Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dravet Syndrome Therapies and Key Companies

TAK-935 (soticlestat): Takeda
BELVIQ (lorcaserin): Eisai
STK-001: Stoke Therapeurtics
EPX-100: EpyGenix Therapeutics
ganaxolone: Marinus Pharmaceuticals
EPX-100 (Clemizole HCl): Epygenix
STK-001: Stoke Therapeutics, Inc
ZX008 (Fenfluramine Hydrochloride): Zogenix International Ltd, Inc.
Soticlestat: Takeda
GWP42003-P: Jazz Pharmaceuticals
Soticlestat: Ovid Therapeutics Inc.
LP352: Longboard Pharmaceuticals

Discover more about therapies set to grab major Dravet Syndrome market share @ Dravet Syndrome Treatment Market

Dravet Syndrome Market Strengths

The researchers are undergoing advancement in already approved drugs by providing an alternative means of delivering the drug.
A broader awareness among health care providers and the public for better treatments helps to improve care and outcomes.
Development of long-acting injectable Antipsychotics.

Dravet Syndrome Market Opportunities

Demands of advanced therapeutics and presence of significant number of pipeline drugs.
There is growing evidence that patients with a dual diagnosis does not respond well to conventional psychiatric treatment, creating demand for a new approach from a different perspective.
Because of the increase in the side effects and less efficacious drug, the demand for specific therapy also increases.

Scope of the Dravet Syndrome Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Dravet Syndrome Therapies: TAK-935 (soticlestat), BELVIQ (lorcaserin), STK-001, ganaxolone, EPX-100 (Clemizole HCl), STK-001, ZX008 (Fenfluramine Hydrochloride), GWP42003-P, Soticlestat, LP352, and others
Dravet Syndrome Therapeutic Assessment: Dravet Syndrome current marketed and Dravet Syndrome emerging therapies
Dravet Syndrome Market Dynamics: Dravet Syndrome market drivers and Dravet Syndrome market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Dravet Syndrome Unmet Needs, KOL’s views, Analyst’s views, Dravet Syndrome Market Access and Reimbursement

To know more about Dravet Syndrome companies working in the treatment market, visit @ Dravet Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

1. Dravet Syndrome Market Report Introduction

2. Executive Summary for Dravet Syndrome

3. SWOT analysis of Dravet Syndrome

4. Dravet Syndrome Patient Share (%) Overview at a Glance

5. Dravet Syndrome Market Overview at a Glance

6. Dravet Syndrome Disease Background and Overview

7. Dravet Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Dravet Syndrome

9. Dravet Syndrome Current Treatment and Medical Practices

10. Dravet Syndrome Unmet Needs

11. Dravet Syndrome Emerging Therapies

12. Dravet Syndrome Market Outlook

13. Country-Wise Dravet Syndrome Market Analysis (2020–2034)

14. Dravet Syndrome Market Access and Reimbursement of Therapies

15. Dravet Syndrome Market Drivers

16. Dravet Syndrome Market Barriers

17. Dravet Syndrome Appendix

18. Dravet Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dravet Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Eisai, Stoke Therapeutics, EpyGenix Therapeutic, Marinus Pharma, Stoke Therapeutics, Jazz Pharma

Non-Small Cell Lung Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca

The Key Non-Small Cell Lung Cancer Companies in the market include – Merck, AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Merck Sharp & Dohme LLC, Arcus Biosciences, Inc., Ono Pharmaceutical Co. Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others.

DelveInsight’s “Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Non-Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Small Cell Lung Cancer Market Forecast

Some of the key facts of the Non-Small Cell Lung Cancer Market Report:

The Non-Small Cell Lung Cancer market size was valued ~USD 30 billion in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In January 2025, The U.S. Food and Drug Administration (FDA) has granted priority review to Dizal’s new drug application (NDA) for Sunvozertinib, intended for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
In December 2024, Nuvation Bio Inc., a global biopharmaceutical company dedicated to addressing unmet oncology needs, announced that the U.S. FDA has accepted its New Drug Application (NDA) for taletrectinib. This investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) is being assessed for the treatment of advanced ROS1-positive non-small cell lung cancer (NSCLC), regardless of prior treatment history.
In December 2024, Merus N.V. announced that the FDA has approved BIZENGRI® (zenocutuzumab-zbco), the first and only treatment for adults with advanced unresectable or metastatic pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) with a neuregulin 1 (NRG1) gene fusion, following disease progression after prior systemic therapy.
In November 2024, AstraZeneca’s Tagrisso (osimertinib) has received a positive recommendation for approval in the European Union (EU) for treating adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC). This approval applies to patients whose tumors exhibit epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has remained stable during or after platinum-based chemoradiation therapy (CRT).
The market size for PD-L1 expressing non-small cell lung cancer (NSCLC) in the 7MM is projected to reach approximately USD 15,000 million by 2024, surpassing EGFR and KRAS.
In 2024, the estimated market size for EGFR-mutated NSCLC in the US was approximately USD 2,900 million, with anticipated growth driven by emerging therapies and label expansions of existing treatments.
In 2024, the United States recorded around 204,800 new cases of NSCLC, with approximately 115,500 cases in men and 89,300 in women.
In 2024, NSCLC was more prevalent among individuals aged 65 years and older compared to those under 65, with approximately 140,000 cases reported in this age group in the US.
Currently, ALECENSA and ALUNBRIG are the preferred first-line ALK TKIs, with ALECENSA being significantly more widely used and leading the ALK market. Before their introduction, XALKORI was the primary first-line treatment for ALK-positive patients.
Key Non-Small Cell Lung Cancer Companies: Merck, AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Merck Sharp & Dohme LLC, Arcus Biosciences, Inc., Ono Pharmaceutical Co. Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others
Key Non-Small Cell Lung Cancer Therapies: KEYTRUDA (pembrolizumab), Telisotuzumab Vedotin, Ensartinib (X-396), SAR408701, Hyleukin-7 (NT-I7;Efineptakin Alfa), Avelumab (Bavencio), Sitravatinib, Trastuzumab deruxtecan, DS-1062a, Durvalumab, Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Domvanalimab, ONO-4538, M7824, Retifanlimab, Lenvatinib, and others
The Non-Small Cell Lung Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Small Cell Lung Cancer pipeline products will significantly revolutionize the Non-Small Cell Lung Cancer market dynamics.

Non-Small Cell Lung Cancer Overview

Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. It is a category of epithelial lung cancer that includes several subtypes with similar treatment approaches and prognoses.

Get a Free sample for the Non-Small Cell Lung Cancer Market Report:

https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market

Non-Small Cell Lung Cancer Epidemiology

Non-Small Cell Lung Cancer Epidemiology Segmentation:

The Non-Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Non-Small Cell Lung Cancer
Prevalent Cases of Non-Small Cell Lung Cancer by severity
Gender-specific Prevalence of Non-Small Cell Lung Cancer
Diagnosed Cases of Episodic and Chronic Non-Small Cell Lung Cancer

Download the report to understand which factors are driving Non-Small Cell Lung Cancer epidemiology trends @ Non-Small Cell Lung Cancer Epidemiology Forecast

Non-Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers Non-Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Non-Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Non-Small Cell Lung Cancer Therapies and Key Companies

KEYTRUDA (pembrolizumab): Merck
Telisotuzumab Vedotin: AbbVie
Ensartinib (X-396): Xcovery
SAR408701: Sanofi
Hyleukin-7 (NT-I7;Efineptakin Alfa): NeoImmune Tech
Avelumab (Bavencio): Merck KGaA and Pfizer
Sitravatinib: Mirati Therapeutics
Trastuzumab deruxtecan: AstraZeneca
DS-1062a: Daiichi Sankyo, Inc.
Durvalumab: Parexel
Sacituzumab Govitecan-hziy (SG): Gilead Sciences
Pembrolizumab: Merck Sharp & Dohme LLC
Domvanalimab: Arcus Biosciences, Inc.
ONO-4538: Ono Pharmaceutical Co. Ltd
M7824: EMD Serono
Retifanlimab: Incyte Corporation
Lenvatinib: Eisai Inc.

To know more about Non-Small Cell Lung Cancer companies working in the treatment market, visit @ Non-Small Cell Lung Cancer Clinical Trials and Therapeutic Assessment

Non-Small Cell Lung Cancer Market Drivers

Premium-price targeted agents with better clinical profile and expansion of therapies in the first-line expected to drive the growth of NSCLC market
The development of therapies targeting specific mutations are expected to dominate the upcoming market

Non-Small Cell Lung Cancer Market Barriers

Potential for premium pricing of emerging therapies by showing an edge over current therapies Uptake of potential emerging therapies with better clinical profile, specificity towards mutations occurs in NSCLC and therapies to overcome resistance expected to be fast

Scope of the Non-Small Cell Lung Cancer Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Non-Small Cell Lung Cancer Companies: Merck, AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Merck Sharp & Dohme LLC, Arcus Biosciences, Inc., Ono Pharmaceutical Co. Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others
Key Non-Small Cell Lung Cancer Therapies: KEYTRUDA (pembrolizumab), Telisotuzumab Vedotin, Ensartinib (X-396), SAR408701, Hyleukin-7 (NT-I7;Efineptakin Alfa), Avelumab (Bavencio), Sitravatinib, Trastuzumab deruxtecan, DS-1062a, Durvalumab, Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Domvanalimab, ONO-4538, M7824, Retifanlimab, Lenvatinib, and others
Non-Small Cell Lung Cancer Therapeutic Assessment: Non-Small Cell Lung Cancer current marketed and Non-Small Cell Lung Cancer emerging therapies
Non-Small Cell Lung Cancer Market Dynamics: Non-Small Cell Lung Cancer market drivers and Non-Small Cell Lung Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Non-Small Cell Lung Cancer Unmet Needs, KOL’s views, Analyst’s views, Non-Small Cell Lung Cancer Market Access and Reimbursement

Discover more about therapies set to grab major Non-Small Cell Lung Cancer market share @ Non-Small Cell Lung Cancer Treatment Market

Table of Contents

1. Non-Small Cell Lung Cancer Market Report Introduction

2. Executive Summary for Non-Small Cell Lung Cancer

3. SWOT analysis of Non-Small Cell Lung Cancer

4. Non-Small Cell Lung Cancer Patient Share (%) Overview at a Glance

5. Non-Small Cell Lung Cancer Market Overview at a Glance

6. Non-Small Cell Lung Cancer Disease Background and Overview

7. Non-Small Cell Lung Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Non-Small Cell Lung Cancer

9. Non-Small Cell Lung Cancer Current Treatment and Medical Practices

10. Non-Small Cell Lung Cancer Unmet Needs

11. Non-Small Cell Lung Cancer Emerging Therapies

12. Non-Small Cell Lung Cancer Market Outlook

13. Country-Wise Non-Small Cell Lung Cancer Market Analysis (2020–2034)

14. Non-Small Cell Lung Cancer Market Access and Reimbursement of Therapies

15. Non-Small Cell Lung Cancer Market Drivers

16. Non-Small Cell Lung Cancer Market Barriers

17. Non-Small Cell Lung Cancer Appendix

18. Non-Small Cell Lung Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Small Cell Lung Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca

Viscosupplementation Devices Market Set to Expand at a Robust CAGR of 7.94% by 2030, According to DelveInsight Report

“Viscosupplementation Devices Market”

Companies like KiOmed Pharma, BioPolymer GmbH & Co KG, ALBOMED® GmbH, and Juniper Biologics are advancing Viscosupplementation Devices, improving diagnosis and patient outcomes.

DelveInsight’s “Viscosupplementation Devices Market Insights, Competitive Landscape, and Market Forecast–2030” report provides a comprehensive analysis of the global viscosupplementation devices market, focusing on adoption trends, technological advancements, and market dynamics across key regions. The report examines the market’s growth trajectory, offering historical and projected market sizes, revenue trends, and critical factors driving the demand for viscosupplementation devices in osteoarthritis treatment.

The report presents vital statistics on the current market landscape and highlights emerging innovations in viscosupplementation technology. It explores how advancements in hyaluronic acid formulations, combination therapies, and extended-release injectables are improving treatment efficacy, prolonging pain relief, and enhancing patient outcomes, making viscosupplementation a key non-surgical solution for osteoarthritis management.

Additionally, the report evaluates the competitive landscape, profiling major players in the global viscosupplementation devices market while also highlighting emerging technologies and solutions expected to drive market growth. It provides an in-depth review of ongoing clinical developments, regulatory progress, and novel product launches in the viscosupplementation segment. This report serves as an essential resource for understanding the evolving dynamics of the viscosupplementation devices market and forecasting its future direction.

To know in detail about the Viscosupplementation Devices market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Viscosupplementation Devices Market Forecast Report

Some of the key insights of the Viscosupplementation Devices Market Report:

• The viscosupplementation devices market, valued at USD 4.08 billion in 2023, is projected to grow at a CAGR of 7.94%, reaching approximately USD 6.43 billion by 2030.

• Osteoarthritis cases in the US have been rising, reaching approximately 38.6 million in 2023, increasing the demand for viscosupplementation devices.

• North America is estimated to hold a significant revenue share in the Viscosupplementation Devices market.

• In July 2024, Anika announced the full market release of the Integrity™ Implant System, a regenerative hyaluronic acid-based scaffold used for repairing rotator cuff and other tendon injuries.

• Key players in the global Viscosupplementation Devices market include Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Sanofi, Smith & Nephew, Ferring B.V., Lifecore Biomedical, LLC, LG Chem, Fidia Farmaceutici S.p.A, OrthogenRx, Bioventus, DePuy Synthes (Johnson & Johnson), Vivacy, APTISSEN, KiOmed Pharma, BioPolymer GmbH & Co KG, ALBOMED® GmbH, Juniper Biologics, Ono Pharmaceutical Co., Ltd., CarthroniX, Zimmer Biomet, and others.

Viscosupplementation Devices Overview

Viscosupplementation devices are used to relieve joint pain, primarily in osteoarthritis patients, by injecting hyaluronic acid (HA) into affected joints to enhance lubrication and cushioning. This minimally invasive treatment improves mobility and delays the need for surgical interventions. The growing prevalence of osteoarthritis, an aging population, and increasing patient preference for non-surgical pain management drive market growth. Advances in HA formulations, including cross-linked and combination therapies, are enhancing efficacy and patient outcomes. Additionally, rising awareness, government initiatives, and continuous innovation in viscosupplementation solutions are further boosting adoption and market expansion.

Get a Free sample for the Viscosupplementation Devices Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/viscosupplementation-devices-market

Viscosupplementation Devices Market Segment Analysis:

The Viscosupplementation Devices market report offers market segment analysis for the forecast period 2024-2030, segmented into:

• Viscosupplementation Devices Market by Product Type (Single Injection, Three Injections, and Five Injections)

• Viscosupplementation Devices Market by End-User (Hospitals, Orthopedic Clinics, and Others)

• Viscosupplementation Devices Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Download the Viscosupplementation Devices Market Analysis report for key market trends, innovations, and growth drivers.

Viscosupplementation Devices Market Dynamics

By 2050, nearly one billion people are expected to have osteoarthritis (OA), with knee and hip OA seeing the highest increases. This rising prevalence is driving demand for viscosupplementation devices, which offer non-surgical pain relief through hyaluronic acid injections that enhance joint lubrication and function.

Market growth is further propelled by strategic industry advancements. In December 2023, Bioventus Inc. secured a nationwide contract with Aetna™ Medicare Advantage, enabling over 3 million members to access DUROLANE, a single-injection HA treatment for knee OA. Innovations in HA formulations, such as cross-linked HA for prolonged relief and combination therapies like Cingal, are enhancing efficacy and patient outcomes.

Despite these advancements, competition from alternative OA treatments, including pain medications, physical therapy, and PRP therapy, along with concerns about injection-related discomfort and infection risks, may limit adoption. However, the viscosupplementation market remains poised for significant expansion.

North America Set to Lead the Growth of the Global Viscosupplementation Devices Market

North America is anticipated to lead the viscosupplementation devices market, driven by the rising prevalence of osteoarthritis and an aging population. Increasing awareness programs, government initiatives, and product approvals further contribute to market growth. With a growing preference for non-surgical pain management options, viscosupplementation devices offer a minimally invasive solution for joint pain relief. Additionally, advancements in product development and regulatory approvals are expected to enhance accessibility and adoption. These factors collectively support the expansion of the viscosupplementation devices market in the region.

Viscosupplementation Devices Market Drivers

• The increasing incidence of osteoarthritis, particularly among the elderly, is driving demand for viscosupplementation devices as a non-surgical treatment option to manage joint pain and improve mobility.

• Continuous innovations, such as cross-linked HA and combination therapies (e.g., HA with corticosteroids), are enhancing treatment efficacy, prolonging pain relief, and improving patient outcomes, fueling market expansion.

Viscosupplementation Devices Market Barriers

• The presence of other non-surgical treatments, such as physical therapy, pain medications, and platelet-rich plasma (PRP) therapy, may limit the widespread adoption of viscosupplementation devices.

• Patients may experience discomfort, inflammation, or infection at the injection site, leading to hesitation in opting for viscosupplementation, thereby impacting market growth.

To learn more about Viscosupplementation Devices drivers and barriers, visit @ Viscosupplementation Devices Competitive Landscape and Market Forecast Report

Table of Contents

1. Viscosupplementation Devices Market Report Introduction

2. Viscosupplementation Devices Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Viscosupplementation Devices Market Key Factors Analysis

6. Viscosupplementation Devices Market Porter’s Five Forces Analysis

7. Viscosupplementation Devices Market Layout

8. Viscosupplementation Devices Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Viscosupplementation Devices Market Set to Expand at a Robust CAGR of 7.94% by 2030, According to DelveInsight Report

Surgical Site Infections Market Poised for Transformative Growth by 2034, Predicts DelveInsight

“Surgical Site Infections Market”

The Surgical Site Infections market is steadily advancing, driven by evolving treatment strategies and ongoing research. DelveInsight’s latest 7MM report offers in-depth insights into key epidemiology trends and market dynamics.

DelveInsight’s “Surgical Site Infections – Market Insight, Epidemiology, And Market Forecast – 2034″ report offers an in-depth understanding of the Surgical Site Infections, historical and forecasted epidemiology as well as the Surgical Site Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Some of the key facts of the Surgical Site Infections Market Report:

• According to DelveInsight, the market for Surgical Site Infections in the 7MM is expected to witness notable growth during the study period from 2020 to 2034.

• According to findings, cigarette smoking has a negative impact on wound healing in orthopedic surgery, with an increase in the incidence of surgical site infection of 7%.

• Research indicates that surgical site infections occur in 2% to 4% of all patients undergoing inpatient surgical procedures.

• The overall incidence of surgical site infections was around 10% in the early 2000s, gradually decreasing to 7% by 2007 and further dropping to 5% by 2020.

• In March 2025, PolyPid Ltd. announced the successful completion of enrollment in the SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing surgical site infections in patients undergoing abdominal colorectal surgery.

• In August 2024, Guard Medical Inc. announced FDA 510(k) clearance for larger sizes of its NPseal Negative Pressure Wound Therapy (NPWT) dressing, now available for surgical wounds up to 25cm. NPseal is a user-friendly, affordable dressing with an integrated pump that quickly establishes and maintains negative pressure.

• Emerging therapies in the Surgical Site Infections Treatment Market focus on innovations like PolyPid’s D-PLEX100 for localized antibiotic delivery and Destiny Pharma’s XF-73 antimicrobial peptides, aiming to reduce infections and fight antibiotic resistance.

• Leading companies in the Surgical Site Infections market include Destiny Pharma, PolyPid, Menarini Group Pharma, Botanix Pharma, Dr. Reddy’s Laboratories Ltd., Zurex Pharma, and others.

• The rising number of radiation therapy patients and advancements in therapeutic options continue to drive the demand for effective Surgical Site Infections treatments.

To know in detail about the Surgical Site Infections market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Surgical Site Infections Market Forecast

Surgical Site Infections Overview

A surgical site infection (SSI) is an infection that develops at or near the incision site following a surgical procedure, potentially affecting different tissue layers. Common symptoms include redness, swelling, pain, fever, and the discharge of cloudy or purulent fluid. SSIs typically emerge within 30 days post-surgery and are categorized by the Centers for Disease Control and Prevention (CDC) into three types:

Superficial Incisional SSI: Affects the skin and subcutaneous tissue at the incision site.

Deep Incisional SSI: Involves deeper layers such as muscles and surrounding tissues.

Organ or Space SSI: Occurs in internal organs or spaces manipulated during surgery.

Diagnosis relies on clinical evaluation, wound cultures to identify infectious agents, and imaging techniques if deeper infections are suspected. Prompt identification and treatment are essential to managing SSIs and preventing complications.

Get a Free sample for the Surgical Site Infections Market Report:https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market

Surgical Site Infections Epidemiology

Surgical Site Infections Epidemiology Segmentation:

The Surgical Site Infections epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

• Total Incident Cases of Surgical Site Infections

• Type-specific Cases of Surgical Site Infections,

• Organ-specific Cases of Surgical Site Infections

• Treated Cases of Surgical Site Infections

Download the report to understand which factors are driving Surgical Site Infections epidemiology trends @ Surgical Site Infections Epidemiology Forecast

Surgical Site Infections Drugs Uptake, and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Surgical Site Infections market or expected to be launched during the study period. The analysis covers the Surgical Site Infections market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Surgical Site Infections Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Surgical Site Infections Market Strengths

• Increased awareness among healthcare professionals and patients, along with the implementation of stringent infection control protocols, has significantly contributed to reducing surgical site infections (SSIs). Advancements in antiseptic techniques, sterilization methods, and infection surveillance programs further strengthen the market.

• The development and adoption of novel antimicrobial-coated sutures, wound dressings, and advanced therapies such as negative pressure wound therapy (NPWT) have enhanced infection prevention and management, driving market growth.

Surgical Site Infections Market Weaknesses

• The implementation of advanced infection prevention strategies, including antimicrobial dressings, surveillance systems, and prophylactic antibiotic administration, can be costly, posing a challenge for healthcare facilities with limited budgets, especially in low- and middle-income countries.

• The growing concern over antimicrobial resistance (AMR) limits the effectiveness of traditional antibiotic therapies for SSIs, making treatment more challenging and increasing the need for novel antimicrobial strategies, which may take longer to develop and commercialize.

Scope of the Surgical Site Infections Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Surgical Site Infections Therapies: D-PLEX100, XF-73 Nasal gel, and others.

• Key Surgical Site Infections Companies: Destiny Pharma, PolyPid, Menarini Group Pharma, Botanix Pharma, Dr. Reddy’s Laboratories Ltd., Zurex Pharma, and others.

• Surgical Site Infections Therapeutic Assessment: Surgical Site Infections currently marketed and Surgical Site Infections emerging therapies

• Surgical Site Infections Market Dynamics: Surgical Site Infections market drivers and Surgical Site Infections market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Surgical Site Infections Unmet Needs, KOL’s views, Analyst’s views, Surgical Site Infections Market Access and Reimbursement

To learn more about the key players and advancements in the Surgical Site Infections Treatment Landscape, visit the Surgical Site Infections Market Analysis Report

Table of Contents

1. Surgical Site Infections Market Report Introduction

2. Executive Summary for Surgical Site Infections

3. SWOT analysis of Surgical Site Infections

4. Surgical Site Infections Patient Share (%) Overview at a Glance

5. Surgical Site Infections Market Overview at a Glance

6. Surgical Site Infections Disease Background and Overview

7. Surgical Site Infections Epidemiology and Patient Population

8. Country-Specific Patient Population of Surgical Site Infections

9. Surgical Site Infections Current Treatment and Medical Practices

10. Surgical Site Infections Unmet Needs

11. Surgical Site Infections Emerging Therapies

12. Surgical Site Infections Market Outlook

13. Country-Wise Surgical Site Infections Market Analysis (2020–2034)

14. Surgical Site Infections Market Access and Reimbursement of Therapies

15. Surgical Site Infections Market Drivers

16. Surgical Site Infections Market Barriers

17. Surgical Site Infections Appendix

18. Surgical Site Infections Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Surgical Site Infections Market Poised for Transformative Growth by 2034, Predicts DelveInsight

Negative Pressure Wound Therapy Systems Market Poised for Steady Growth, Projected to Achieve a Strong CAGR Through 2030, Reports DelveInsight

“Negative Pressure Wound Therapy Systems Market”

Companies like Lohmann & Rauscher, Cenefom Corp, and PAUL HARTMANN Asia-Pacific Ltd. are advancing negative pressure wound therapy systems and improving diagnosis and patient outcomes.

DelveInsight’s “Negative Pressure Wound Therapy Systems Market Insights, Competitive Landscape, and Market Forecast–2030” report provides a comprehensive analysis of the global NPWT systems market, focusing on adoption trends, technological advancements, and market dynamics across key regions. The report examines the market’s growth trajectory, offering historical and projected market sizes, revenue trends, and critical factors driving the demand for NPWT systems in wound management.

The report presents vital statistics on the current market landscape and highlights emerging innovations in NPWT technology. It explores how advancements in portable and disposable NPWT devices, smart monitoring systems, and improved dressing materials are enhancing wound healing, reducing infection risks, and improving patient outcomes, making NPWT a critical solution for chronic and acute wound care.

Additionally, the report evaluates the competitive landscape, profiling major players in the global NPWT systems market while also highlighting emerging technologies and solutions expected to drive market growth. It provides an in-depth review of ongoing clinical developments, regulatory progress, and novel product launches in the NPWT segment. This report serves as an essential resource for understanding the evolving dynamics of the NPWT systems market and forecasting its future direction.

To know in detail about the Negative Pressure Wound Therapy Systems market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Negative Pressure Wound Therapy Systems Market Forecast Report

Some of the key insights of the Negative Pressure Wound Therapy Systems Market Report:

• The Negative Pressure Wound Therapy Systems market, valued at USD 4.08 billion in 2023, is projected to grow at a CAGR of 7.94%, reaching approximately USD 6.43 billion by 2030.

• Osteoarthritis cases in the US have been rising, reaching approximately 38.6 million in 2023, increasing the demand for Negative Pressure Wound Therapy Systems.

• North America is estimated to hold a significant revenue share in the Negative Pressure Wound Therapy Systems market.

• In April 2024, Smith & Nephew PLC launched its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US. The NPWT System was designed to enhance home-based care for patients with chronic wounds, including ulcers. Lightweight, compact, and discreet, the system could be easily carried or worn, operated quietly, and featured a canister.

• In April 2024, Smith & Nephew PLC announced the publication of a study demonstrating that its ALLEVYN LIFE foam dressing featured a novel mechanism of action for pressure injury prevention (PIP). The study revealed that the ALLEVYN LIFE foam dressing had layers capable of sliding independently, which absorbed mechanical energy that might otherwise have harmed the patient. This sliding action reduces pressure on the skin and underlying tissues.

• Key players in the global Negative Pressure Wound Therapy Systems market include 3M, Cardinal Health, ConvaTec Group PLC, DeRoyal Industries, Inc., Devon Group, Medela AG, Smith & Nephew PLC, Mölnlycke Health Care AB, Talley Group Ltd., Accel-Heal Technologies Ltd., B. Braun Melsungen AG, Lohmann & Rauscher, Cenefom Corp, PAUL HARTMANN Asia-Pacific Ltd., Carilex Medical, Chongqing Sunshine Medical Industry and Trading Co., Ltd., Foryou Medical Electronics Co., Ltd., Innovative Therapies, Genadyne, Cork Medical, LLC, and others.

Negative Pressure Wound Therapy Systems Overview

Negative Pressure Wound Therapy (NPWT) systems are advanced wound care solutions that utilize controlled suction to promote healing in chronic, acute, and surgical wounds. By applying negative pressure through a sealed dressing, these systems help remove excess exudate, reduce edema, improve blood circulation, and accelerate tissue regeneration. NPWT is widely used in treating diabetic foot ulcers, pressure ulcers, burns, and post-surgical wounds, offering a non-invasive and effective approach to wound management. Continuous advancements, such as portable and disposable NPWT devices, are expanding its applications, improving patient comfort, and optimizing treatment outcomes.

Get a Free sample for the Negative Pressure Wound Therapy Systems Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/negative-pressure-wound-therapy-systems-market

Negative Pressure Wound Therapy Systems Market Segment Analysis:

The Negative Pressure Wound Therapy Systems market report offers market segment analysis for the forecast period 2024-2030, segmented into:

• Negative Pressure Wound Therapy Systems Market by Product Type (Conventional NPWT Devices, Single-Use NPWT Devices)

• Negative Pressure Wound Therapy Systems Market by Wound Type (Pressure Ulcers, Diabetic Ulcers, and Venous Ulcers)

• Negative Pressure Wound Therapy Systems Market by End-User (Hospitals, Specialty Clinics, and Others)

• Negative Pressure Wound Therapy Systems Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World).

Download the Negative Pressure Wound Therapy Systems Market Analysis report for key market trends, innovations, and growth drivers.

Negative Pressure Wound Therapy Systems Market Dynamics

The rising prevalence of diabetic foot ulcers and surgical wounds is driving the demand for negative pressure wound therapy (NPWT) systems. In regions like Australia and Africa, high rates of diabetic foot disease and amputations highlight the need for advanced wound care solutions. Additionally, countries with high surgical volumes, such as Germany and Finland, increasingly integrate NPWT into post-operative care to enhance healing and reduce complications.

Market growth is further propelled by technological advancements and regulatory approvals. For instance, in April 2023, 3M received FDA clearance for its Veraflo therapy, designed to accelerate wound healing and minimize surgical interventions. Despite its benefits, NPWT systems pose risks like wound dehiscence and infection, which may limit market expansion. However, with ongoing innovation and increasing adoption, the NPWT market is expected to grow steadily through 2030.

North America Set to Lead the Growth of the Global Negative Pressure Wound Therapy Systems Market

North America is expected to lead the negative pressure wound therapy (NPWT) systems market, driven by the rising incidence of traumatic injuries, increasing surgical procedures, and the growing prevalence of diabetes-related complications, including amputations. Advancements in NPWT technology, regulatory support, and innovative product launches are further propelling market growth.

NPWT plays a crucial role in managing complex wounds associated with traumatic injuries and post-surgical care by promoting faster healing and reducing complications. The therapy is also widely used in diabetic wound management, helping to prevent severe outcomes like amputations.

Additionally, continuous product innovations and regulatory approvals are expanding the adoption of NPWT systems across various care settings, including hospitals and home healthcare. The combination of these factors is expected to sustain North America’s dominance in the market over the forecast period.

Negative Pressure Wound Therapy Systems Market Drivers

• The increasing incidence of diabetes, pressure ulcers, and venous leg ulcers is driving demand for NPWT systems. These conditions require effective wound management solutions, positioning NPWT as a preferred treatment option.

• Innovations in portable, single-use, and smart NPWT systems with remote monitoring capabilities enhance treatment efficiency, patient compliance, and healthcare outcomes, contributing to market expansion.

Negative Pressure Wound Therapy Systems Market Barriers

• The cost of NPWT devices, along with associated consumables, can be a significant financial burden, limiting accessibility, particularly in lower-income regions and underfunded healthcare systems.

• Many healthcare providers and patients remain unaware of NPWT benefits or lack proper training for optimal usage, leading to underutilization and slower adoption rates in certain regions.

To learn more about Negative Pressure Wound Therapy Systems drivers and barriers, visit @ Negative Pressure Wound Therapy Systems Competitive Landscape and Market Forecast Report

Table of Contents

1. Negative Pressure Wound Therapy Systems Market Report Introduction

2. Negative Pressure Wound Therapy Systems Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Negative Pressure Wound Therapy Systems Market Key Factors Analysis

6. Negative Pressure Wound Therapy Systems Market Porter’s Five Forces Analysis

7. Negative Pressure Wound Therapy Systems Market Layout

8. Negative Pressure Wound Therapy Systems Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

About DelveInsight

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Negative Pressure Wound Therapy Systems Market Poised for Steady Growth, Projected to Achieve a Strong CAGR Through 2030, Reports DelveInsight

Hemophilia B Drugs Market Set for Transformative Growth by 2034, Predicts DelveInsight

“Hemophilia B Drugs Market”

The hemophilia B market is steadily advancing, driven by evolving treatment strategies and ongoing research. DelveInsight’s latest 7MM report offers in-depth insights into key epidemiology trends and market dynamics.

DelveInsight’s “Hemophilia B – Market Insight, Epidemiology, And Market Forecast – 2034″ report offers an in-depth understanding of the Hemophilia B, historical and forecasted epidemiology as well as the Hemophilia B market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Some of the key facts of the Hemophilia B Market Report:

• According to DelveInsight, the market for Hemophilia B in the 7MM is expected to witness notable growth during the study period from 2020 to 2034.

• In 2023, the US had the highest diagnosed prevalent cases of Hemophilia B among the 7MM, with around 4K cases, expected to rise during the forecast period.

• Among EU4 and the UK, France reported the highest cases, while Germany had the lowest.

• In the US, Hemophilia B was most common in the 19–44 age group, comprising about 35% of total cases.

• In December 2024, Novo announced that the FDA approved concizumab, its tissue factor pathway inhibitor (TFPI) antagonist, as a once-daily treatment to prevent or reduce bleeding episodes in patients aged 12 and older with hemophilia A or B with inhibitors.

• In October 2024, Pfizer Inc. announced that the FDA has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis in adults and pediatric patients aged 12 and older with hemophilia A or B, without FVIII or FIX inhibitors.

• In October 2024, Novo Nordisk received support from European regulators for the approval of its anti-TFPI antibody, Alhemo (concizumab), as a preventive treatment for hemophilia. The company stated that, if approved, this therapy would provide the first subcutaneous prophylactic treatment to be administered once daily for individuals with hemophilia A or B who have inhibitors.

• Emerging hemophilia B drugs include Fitusiran, Marstacimab, SerpinPC, and others.

• Leading companies in the Hemophilia B market include UniQure Biopharma B.V., CSL Behring, Pfizer/Spark Therapeutics, Genzyme, a Sanofi Company, Alnylam Pharmaceuticals, Novo Nordisk, Pfizer, UniQure Biopharma B.V., ApcinteX Ltd, Freeline Therapeutics, Sangamo Therapeutics, and others.

• The rising number of radiation therapy patients and advancements in therapeutic options continue to drive the demand for effective Hemophilia B treatments.

To know in detail about the Hemophilia B market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Hemophilia B Market Forecast

Hemophilia B Overview

Hemophilia B, also known as Christmas disease, is a rare genetic bleeding disorder caused by a deficiency of factor IX, a crucial clotting protein needed for blood coagulation. The severity of the condition depends on the levels of factor IX in the blood. While there is no cure, treatment focuses on managing symptoms and enhancing quality of life. Ongoing research aims to develop advanced therapies and improve disease understanding.

Get a Free sample for the Hemophilia B Market Report: https://www.delveinsight.com/report-store/hemophilia-b-market

Hemophilia B Epidemiology

Hemophilia B Epidemiology Segmentation:

The Hemophilia B epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

• Total Diagnosed Prevalent Cases of Hemophilia B in the 7MM

• Severity-Specific Prevalent Cases of Hemophilia B in the 7MM

• Age-Specific Prevalent Cases of Hemophilia B in the 7MM

• Prevalent Cases of Hemophilia B with or without Inhibitors in the 7MM

• Treated Patient Pool of Hemophilia B in the 7MM

Download the report to understand which factors are driving Hemophilia B epidemiology trends @ Hemophilia B Epidemiology Forecast

Hemophilia B Drugs Uptake, and Pipeline Development Activities

The Hemophilia B drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia B market or expected to be launched during the study period. The analysis covers the Hemophilia B market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Hemophilia B Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hemophilia B Market Strengths

• Continuous innovation in hemophilia B drugs, including gene therapies and extended half-life treatments, is improving patient outcomes and reducing treatment burden. These advancements drive market growth by offering more effective and long-lasting solutions.

• The hemophilia B market benefits from a robust pipeline of novel therapies, with multiple drug candidates receiving regulatory approvals. The introduction of breakthrough treatments enhances market expansion and provides patients with more therapeutic options.

Hemophilia B Market Weaknesses

• Hemophilia B drugs, particularly gene therapies and recombinant factor IX treatments, are expensive, limiting access for many patients. The high cost of lifelong treatment poses a significant economic burden on healthcare systems and individuals.

• Despite advancements, hemophilia B remains underdiagnosed in many regions due to limited awareness and access to specialized healthcare. Delayed diagnosis and inadequate treatment can lead to severe complications, impacting disease management and market penetration.

Scope of the Hemophilia B Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Hemophilia B Therapies: Fitusiran, Marstacimab, SerpinPC, and others.

• Key Hemophilia B Companies: UniQure Biopharma B.V., CSL Behring, Pfizer/Spark Therapeutics, Genzyme, a Sanofi Company, Alnylam Pharmaceuticals, Novo Nordisk, Pfizer, UniQure Biopharma B.V., ApcinteX Ltd, Freeline Therapeutics, Sangamo Therapeutics, and others.

• Hemophilia B Therapeutic Assessment: Hemophilia B currently marketed and Hemophilia B emerging therapies

• Hemophilia B Market Dynamics: Hemophilia B market drivers and Hemophilia B market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Hemophilia B Unmet Needs, KOL’s views, Analyst’s views, Hemophilia B Market Access and Reimbursement

To learn more about the key players and advancements in the Hemophilia B Treatment Landscape, visit the Hemophilia B Market Analysis Report

Table of Contents

1. Hemophilia B Market Report Introduction

2. Executive Summary for Hemophilia B

3. SWOT analysis of Hemophilia B

4. Hemophilia B Patient Share (%) Overview at a Glance

5. Hemophilia B Market Overview at a Glance

6. Hemophilia B Disease Background and Overview

7. Hemophilia B Epidemiology and Patient Population

8. Country-Specific Patient Population of Hemophilia B

9. Hemophilia B Current Treatment and Medical Practices

10. Hemophilia B Unmet Needs

11. Hemophilia B Emerging Therapies

12. Hemophilia B Market Outlook

13. Country-Wise Hemophilia B Market Analysis (2020–2034)

14. Hemophilia B Market Access and Reimbursement of Therapies

15. Hemophilia B Market Drivers

16. Hemophilia B Market Barriers

17. Hemophilia B Appendix

18. Hemophilia B Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemophilia B Drugs Market Set for Transformative Growth by 2034, Predicts DelveInsight

Electrophysiology Devices Market Poised for Strong Growth, Projected to Expand at a 9.73% CAGR by 2030, Reports DelveInsight

“Electrophysiology Devices Market”

Companies like GENERAL ELECTRIC COMPANY, Medtronic, Abbott, BIOTRONIK, and Microport Scientific Corporation are advancing electrophysiology devices and improving diagnosis and patient outcomes.

DelveInsight’s “Global Electrophysiology Devices Market Insights, Competitive Landscape, and Market Forecast–2030” report provides a comprehensive analysis of the global electrophysiology devices market, focusing on adoption trends, technological advancements, and market dynamics across key regions. The report examines the market’s growth trajectory, offering historical and projected market sizes, revenue trends, and critical factors driving the demand for electrophysiology devices in cardiac arrhythmia diagnosis and treatment.

The report presents vital statistics on the current market landscape and highlights emerging innovations in electrophysiology technology. It explores how advancements in 3D mapping systems, catheter ablation techniques, and AI-driven diagnostics are improving procedural accuracy, treatment outcomes, and overall patient care, making electrophysiology devices integral to modern cardiology.

Additionally, the report evaluates the competitive landscape, profiling major players in the global electrophysiology devices market while also highlighting emerging technologies and solutions expected to drive market growth. It provides an in-depth review of ongoing clinical developments, regulatory progress, and novel product launches in the electrophysiology segment. This report serves as an essential resource for understanding the evolving dynamics of the electrophysiology devices market and forecasting its future direction.

To know in detail about the Electrophysiology Devices market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Electrophysiology Devices Market Forecast Report

Some of the key insights of the Electrophysiology Devices Market Report:

• The electrophysiology devices market was valued at USD 6.31 billion in 2023 and is projected to grow at a CAGR of 9.73% from 2024 to 2030, reaching approximately USD 9.22 billion by 2030.

• North America is estimated to hold a significant revenue share in the Electrophysiology Devices market.

• In May 2024, Implicity, a leader in remote patient monitoring and cardiac data management, received FDA 510(k) clearance for SignalHF1, an innovative new algorithm within their remote monitoring solution.

• Key players in the global Electrophysiology Devices market include Boston Scientific Corporation, Lepu Medical Technology Co. Ltd., GENERAL ELECTRIC COMPANY, Medtronic, Abbott, BIOTRONIK, Microport Scientific Corporation, Acutus Medical Inc., Imricor, Johnson & Johnson Services, Inc., Baylis Medical Company Inc., Schwarzer Cardiotek GmbH, ATRICURE, INC., CardioFocus, Osypka AG, and others.

Electrophysiology Devices Overview

Electrophysiology (EP) devices are essential tools used in diagnosing and treating heart rhythm disorders, such as atrial fibrillation and other arrhythmias. These devices include diagnostic catheters, ablation systems, 3D mapping technologies, and implantable cardiac monitors, which help healthcare providers assess the electrical activity of the heart and deliver targeted treatments. With advancements in minimally invasive procedures, AI-driven diagnostics, and real-time imaging, electrophysiology devices are improving accuracy, reducing procedural risks, and enhancing patient outcomes. The growing prevalence of cardiovascular diseases, increasing adoption of catheter-based interventions, and ongoing technological innovations continue to drive the demand for electrophysiology devices globally.

Get a Free sample for the Electrophysiology Devices Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/electrophysiology-devices-market

Electrophysiology Devices Market Segment Analysis:

The Electrophysiology Devices market report offers market segment analysis for the forecast period 2024-2030, segmented into:

• Electrophysiology Devices Market by Device (Treatment Devices [Defibrillators, Pacemakers, Cardiac Resynchronization Therapy Devices, Ablation Systems [Radiofrequency, Cryoablation, and Others], and Others], Diagnostic Devices [ECG Monitors [Stress, Rest, and Holter Monitors], EP X-Ray Systems, EP Recording Systems, EP Imaging & Mapping Systems, Implantable Cardiac Monitors, and Others]),

• Electrophysiology Devices Market by Modality (Implantable and External), Application (Ventricular Tachycardia, Atrial Fibrillation, Bradycardia, and Others)

• Electrophysiology Devices Market by End-User (Hospitals, Ambulatory Surgical Centers, and Others)

• Electrophysiology Devices Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Download the Electrophysiology Devices Market Analysis report for key market trends, innovations, and growth drivers.

Electrophysiology Devices Market Dynamics

The global burden of cardiovascular diseases, including atrial fibrillation and coronary artery disease, continues to rise, driving demand for advanced electrophysiology devices. Electrophysiology plays a crucial role in diagnosing and managing heart rhythm disorders through technologies like electrocardiography and catheter ablation, enabling personalized treatment and better patient outcomes.

Market growth is further fueled by continuous innovation and product development. For instance, in 2024, GE HealthCare introduced the Prucka 3 and CardioLab EP Recording system, enhancing arrhythmia diagnosis and treatment precision. Additionally, the aging global population, increasingly susceptible to heart rhythm disorders, underscores the need for improved diagnostic and therapeutic solutions.

Despite these advancements, challenges such as procedural complications and the availability of alternative treatments may limit market expansion. However, the growing prevalence of cardiovascular diseases and technological advancements are expected to drive the electrophysiology devices market forward.

North America Set to Lead the Growth of the Global Electrophysiology Devices Market

North America is expected to hold a significant share of the electrophysiology devices market, driven by the high prevalence of cardiovascular diseases such as coronary artery disease and myocardial infarctions. The region’s growing burden of heart conditions, coupled with key risk factors like high blood pressure, cholesterol, and smoking, continues to fuel the demand for advanced electrophysiology solutions. Additionally, technological advancements and regulatory approvals are playing a crucial role in enhancing diagnostic and treatment capabilities.

Electrophysiology plays a vital role in diagnosing and managing heart conditions by analyzing the heart’s electrical activity to detect arrhythmias and assess the conduction system. This has led to the development of innovative treatments and devices, including pacemakers and defibrillators, which significantly improve patient care. Furthermore, increasing product development initiatives and regulatory approvals are strengthening the market. Recent innovations, such as at-home electrophysiological monitoring systems, are revolutionizing patient diagnostics by offering more accessible and efficient solutions.

With continuous advancements, rising awareness, and supportive regulatory frameworks, North America is expected to remain a key player in the growth of the electrophysiology devices market in the coming years.

Electrophysiology Devices Market Drivers

• The increasing incidence of atrial fibrillation, coronary artery disease, and other heart rhythm disorders is driving the demand for electrophysiology devices. With a growing aging population and lifestyle-related risk factors such as hypertension and diabetes, the need for advanced cardiac monitoring and treatment solutions continues to rise.

• Innovations in mapping systems, catheter ablation technologies, and AI-driven diagnostic tools are improving the accuracy and efficiency of electrophysiological procedures. The integration of robotics, real-time imaging, and minimally invasive techniques is enhancing patient outcomes, boosting market growth.

Electrophysiology Devices Market Barriers

• The significant costs associated with electrophysiology procedures, including catheter ablation and advanced mapping systems, pose a financial challenge for healthcare providers and patients. Limited reimbursement policies in certain regions further restrict accessibility.

• Potential complications such as infections, perforation, thromboembolism, and procedural risks may deter patients and healthcare providers from opting for electrophysiological interventions. Concerns over safety and the availability of alternative treatment options, such as medication or implantable devices, may limit market adoption.

To learn more about Electrophysiology Devices drivers and barriers, visit @ Electrophysiology Devices Competitive Landscape and Market Forecast Report

Table of Contents

1. Electrophysiology Devices Market Report Introduction

2. Electrophysiology Devices Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Electrophysiology Devices Market Key Factors Analysis

6. Electrophysiology Devices Market Porter’s Five Forces Analysis

7. Electrophysiology Devices Market Layout

8. Electrophysiology Devices Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

About DelveInsight

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Electrophysiology Devices Market Poised for Strong Growth, Projected to Expand at a 9.73% CAGR by 2030, Reports DelveInsight

Golf News Net Joins FreeCast’s Free Channels

A new FAST channel dedicated to golf fans and players launches on FreeCast.

FreeCast is announcing the launch of the Golf News Net on its platform. Golf News Net, or GNN, is now available for free to all FreeCast members, and joins hundreds of free FAST channels already available via the service. As more sports transition to streaming distribution, sports channels remain an important part of FreeCast’s free channel offering.

Originally launched in 2003, Golf News Net covers all the latest news and issues surrounding the game of golf. The channel aims to be at the forefront of the discussions that will shape the sport, making it an ideal place to catch the latest breaking news and stories around golf. Already available on a variety of streaming video and radio platforms, GNN reaches an audience of over 4 million people each month.

Tracy West, FreeCast’s Executive Vice President of Digital Content, discussed the popularity of golf and Golf News Net: “Sports content is becoming more important to streaming services right now, so this is great timing for us to add Golf News Net. Golf is one of those sports with fans and players of all ages. It’s an accessible sport and you can play it for life. That makes this content relevant across the country, and it’s a valuable opportunity for advertisers and product-makers to reach a targeted audience, too.”

Ryan Ballengee, Golf News Net founder and owner, said: “We are thrilled to join the lineup at FreeCast, home to a near-limitless wealth of content, particularly for sports fans. Golf is an increasingly global game, with millions of recreational golfers taking up the sport in recent years. Our programming speaks to the golfer and the competitive golf fan alike, and Golf News Net TV will keep them entertained, informed and up-to-date on everything happening in our sport.”

Media Contact
Company Name: FreeCast Inc.
Contact Person: Kevin Speedy
Email: Send Email
Phone: (407) 374-1607
Address:6901 TPC Drive Suite 200
City: Orlando
State: Florida
Country: United States
Website: https://freecast.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Golf News Net Joins FreeCast’s Free Channels

Aptus Plumbing and Gas Expands to the Gold Coast, Bringing 5-Star Service to More Queensland Homes and Businesses

“Aptus Plumbing & Gas – Plumbers Brisbane”

Aptus Plumbing and Gas, a trusted leader in Brisbane’s plumbing and gas industry, has expanded its operations with a new office on the Gold Coast. This strategic move extends the company’s renowned 5-star service from the NSW border to Caboolture, covering Ipswich, Redlands, and surrounding areas.

BRISBANE, Australia – March 26, 2025 – For years, Aptus Plumbing and Gas has built a reputation for excellence, addressing a wide range of plumbing and gas issues — including leaking taps, failed hot water systems, gas emergencies, and more. The company’s professional team is known for its reliable communication, expertise in servicing managed properties and multi-unit complexes, and commitment to delivering first-class service.

Meeting Growing Demand with Unmatched Professionalism

As the company expands its footprint, Aptus remains dedicated to the same high standards of service that have made it a household name in Brisbane. Business owner Brett Mulhall highlights the company’s approach to this growth:

“As we researched our expansion to the Gold Coast, the feedback was clear — customers want professionalism, quality communication, and on‑time service. These have been the cornerstones of our business in Brisbane, and we are excited to bring the same level of excellence to the Gold Coast.”

Aptus Plumbing and Gas prides itself on hand-picking the best tradespeople — not just for their technical expertise, but also for their professionalism, courteous interactions, and commitment to leaving every job site clean and tidy.

Proven Excellence Backed by Over 600 5-Star Reviews

Customer feedback is at the heart of Aptus Plumbing and Gas’s success. With more than 600 authentic 5-star reviews on Google, recurring themes of professionalism, effective communication, and prompt service reinforce the company’s commitment to quality.

Expanding Service Without Compromising Standards

The decision to expand to the Gold Coast was driven by increasing regional demand for reliable, high-quality plumbing and gas services. Aptus Plumbing and Gas is set to support a growing customer base, including residential homeowners, property managers, and commercial complexes.

With a reputation built on expertise, transparency, and customer satisfaction, Aptus Plumbing and Gas continues to invest in cutting‑edge systems and workforce training to uphold its industry-leading standards. The company’s expansion is not just about growing its service area — it’s about raising the bar for plumbing and gas services across Queensland.

About Aptus Plumbing and Gas

Aptus Plumbing and Gas has been a trusted name in Brisbane’s plumbing industry for years, known for delivering exceptional service, reliable solutions, and exceptional customer service. With an expanded service area from the NSW border to Caboolture, Aptus continues to set the benchmark for professionalism and expertise.

Media Contact
Company Name: Aptus Plumbing & Gas – Plumbers Brisbane
Contact Person: John Nayler
Email: Send Email
Phone: (61) 407-151-311
Address:2/41 Deakin St
City: Brendale
State: QLD
Country: Australia
Website: https://www.aptusplumbing.com.au/plumber/gold-coast/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Aptus Plumbing and Gas Expands to the Gold Coast, Bringing 5-Star Service to More Queensland Homes and Businesses

The Law Offices of Justin H. King Strengthens Legal Advocacy for Injury Victims in Rancho Cucamonga

The Law Offices of Justin H. King continues to provide dedicated legal representation for individuals who have suffered serious injuries due to negligence. The firm, which focuses on personal injury law, is committed to helping clients navigate the legal process while seeking fair compensation for their losses. The firm has built a reputation for securing favorable outcomes in complex injury cases through extensive legal knowledge and a client-focused approach.

Dedicated Legal Representation for Car Accident Victims

The aftermath of an auto accident can be overwhelming, leaving victims with physical, emotional, and financial burdens. The firm’s Car Accident Lawyer Rancho Cucamonga services are designed to support individuals facing medical expenses, lost income, and other damages resulting from vehicle collisions. By conducting thorough investigations and working with medical and accident reconstruction experts, the firm builds strong cases to help clients recover the compensation they deserve.

Skilled Advocacy in a Range of Accident Cases

From motor vehicle accidents to pedestrian injuries, legal representation plays a critical role in ensuring that victims receive proper compensation. The firm’s Accident Lawyer Rancho Cucamonga services address a broad spectrum of injury cases, including trucking accidents, bicycle crashes, and wrongful death claims. The firm remains dedicated to holding negligent parties accountable by prioritizing strategic legal action and negotiations.

Legal Support for Rancho Cucamonga Car Crash Victims

The impact of a serious car crash can extend far beyond the initial accident, affecting long-term health and financial stability. With deep knowledge of California personal injury laws, the firm’s Rancho Cucamonga Car Crash Lawyer services focus on advocating for victims and ensuring they receive comprehensive legal support. Whether negotiating with insurance companies or litigating in court, the firm is committed to achieving the best possible outcome for every client.

Commitment to Justice and Client Advocacy

Legal battles following an accident can be complex and require skill and determination. The Law Offices of Justin H. King takes pride in offering compassionate and aggressive representation, ensuring that each case is handled with the attention it deserves. By providing tailored legal strategies and pursuing maximum compensation, the firm continues to be a trusted resource for injury victims in Rancho Cucamonga.

About The Law Offices of Justin H. King

The Law Offices of Justin H. King is a premier personal injury law firm based in Rancho Cucamonga, California. The firm specializes in representing individuals who have suffered serious injuries due to negligence, offering expert legal counsel in cases involving car accidents, trucking collisions, pedestrian injuries, and wrongful death claims. With a strong commitment to client advocacy and justice, the firm provides thorough legal representation to secure fair and just compensation.

Media Contact
Company Name: The Law Offices of Justin H. King
Contact Person: George Cohaff
Email: Send Email
Phone: (909) 297-5001
Address:8301 Utica Ave # 101
City: Rancho Cucamonga
State: CA 91730
Country: United States
Website: https://justinkinglaw.com/